SURMOUNT-1: the landmark obesity trial This 72-week, randomized, double-blind, placebo-controlled trial enrolled 2,539 adults with obesity or overweight with at least one weight-related comorbidity
Collateralization and Vascular Growth BPC 157 is an effective angiogenic factor that enhances endothelial cell proliferation and growth
Body composition changes become visible
Ever wonder why some prenatal supplements (including ours!) contain so much Vitamin B12
the rate-limiting precursor in the bodys glutathione synthesis pathway
The molecule was developed by Frank Ng's group at Monash University and Metabolic Pharmaceuticals in Australia during the 1990s and 2000s as a potential anti-obesity drug intended to isolate the lipolytic region of hGH without activating the growth hormone receptor or raising IGF-1.nnIn published preclinical work, the fragment has been shown to stimulate lipolysis, suppress lipogenesis, and modulate the beta-3 adrenergic receptor pathway in adipose tissue rather than acting through the classical hGH receptor